MRNA
Moderna, Inc. Common Stock
$145.10
장중 · Vol 6.66M · 52주 $22.28–$176.66 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $141.46 · Aug 31, 2026
MRNA 가격 추세
종가
$141.46
시가
$134.10
고가
$144.20
저가
$133.85
30초 브리핑
MRNA 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 80%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E -30.7배
업종 피어 비교 전에는 고평가·저평가를 단정하기 어렵습니다.
20일 평균의 3.6배
평소보다 거래가 활발해 가격 움직임의 확인 강도가 높습니다.
2026-11-05
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
MRNA 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
325 Binney Street · Cambridge, MA, United States · 직원 4,700명
시가총액
$56.03B
Trailing P/E
—
최근 12개월 이익 기준
Forward P/E
-30.7
EPS (TTM)
$-7.98
배당 수익률
—
배당성향
0.0%
베타
0.90
시장과 유사
ROE
-39.0%
P/B
8.28
EV/EBITDA
-23.3
52주 범위
$22.28 – $176.66
현재 위치 80%
거래량
87.32M
20일 평균 24.02M · 3.6배
애널리스트 의견
매수 23%
총 22명 · 0m
DITM LEAPS Analysis
MRNA 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MRNA280121C00075000 | 1/21/28 · 1.4Y | $75.00 | $80.50 | 1.5x | 0.8833 | 18.8% | 4.97% | 83.82% | 231 | 71.97 | |
| MRNA271217C00075000 | 12/17/27 · 1.3Y | $75.00 | $79.73 | 1.6x | 0.8836 | 18.0% | 5.58% | 84.56% | 131 | 71.35 | |
| MRNA271217C00080000 | 12/17/27 · 1.3Y | $80.00 | $76.23 | 1.6x | 0.8708 | 20.8% | 4.53% | 82.54% | 243 | 69.84 | |
| MRNA280121C00080000 | 1/21/28 · 1.4Y | $80.00 | $77.88 | 1.6x | 0.8699 | 22.5% | 4.94% | 84.05% | 357 | 69.10 | |
| MRNA280121C00085000 | 1/21/28 · 1.4Y | $85.00 | $74.60 | 1.6x | 0.8569 | 25.8% | 4.29% | 82.31% | 554 | 67.02 | |
| MRNA271217C00085000 | 12/17/27 · 1.3Y | $85.00 | $73.35 | 1.6x | 0.8568 | 24.6% | 5.04% | 82.06% | 88 | 65.42 | |
| MRNA271217C00090000 | 12/17/27 · 1.3Y | $90.00 | $71.00 | 1.7x | 0.8424 | 29.1% | 5.63% | 82.62% | 52 | 60.86 | |
| MRNA280121C00090000 | 1/21/28 · 1.4Y | $90.00 | $72.25 | 1.6x | 0.8431 | 30.3% | 6.23% | 82.67% | 77 | 60.74 | |
| MRNA271217C00095000 | 12/17/27 · 1.3Y | $95.00 | $68.25 | 1.7x | 0.8282 | 33.6% | 6.59% | 81.92% | 224 | 58.49 | |
| MRNA271217C00100000 | 12/17/27 · 1.3Y | $100.00 | $65.38 | 1.8x | 0.8137 | 38.3% | 5.74% | 80.75% | 723 | 56.35 | |
| MRNA280121C00100000 | 1/21/28 · 1.4Y | $100.00 | $67.00 | 1.7x | 0.8154 | 39.8% | 5.97% | 81.39% | 248 | 54.77 | |
| MRNA280121C00095000 | 1/21/28 · 1.4Y | $95.00 | $69.50 | 1.7x | 0.8293 | 34.8% | 5.76% | 81.84% | 3 | 54.20 | |
| MRNA271217C00105000 | 12/17/27 · 1.3Y | $105.00 | $63.50 | 1.8x | 0.7993 | 44.4% | 6.30% | 81.58% | 499 | 51.28 | |
| MRNA280121C00105000 | 1/21/28 · 1.4Y | $105.00 | $64.75 | 1.7x | 0.8015 | 45.4% | 6.95% | 81.28% | 240 | 50.35 | |
| MRNA271217C00110000 | 12/17/27 · 1.3Y | $110.00 | $61.00 | 1.8x | 0.7846 | 50.3% | 6.56% | 80.86% | 222 | 46.22 | |
| MRNA280121C00110000 | 1/21/28 · 1.4Y | $110.00 | $62.50 | 1.8x | 0.7875 | 51.5% | 6.40% | 80.99% | 205 | 46.12 | |
| MRNA280121C00115000 | 1/21/28 · 1.4Y | $115.00 | $60.05 | 1.8x | 0.7731 | 57.8% | 5.16% | 80.15% | 200 | 42.18 | |
| MRNA271217C00115000 | 12/17/27 · 1.3Y | $115.00 | $59.00 | 1.8x | 0.7703 | 57.0% | 6.78% | 80.99% | 119 | 40.84 | |
| MRNA280121C00120000 | 1/21/28 · 1.4Y | $120.00 | $58.50 | 1.8x | 0.7600 | 65.2% | 6.84% | 80.88% | 221 | 36.83 | |
| MRNA271217C00120000 | 12/17/27 · 1.3Y | $120.00 | $56.75 | 1.9x | 0.7556 | 64.2% | 7.93% | 80.46% | 230 | 36.44 |
재무제표
MRNA 연간 손익·현금흐름·재무상태
매출 성장률
-39.9%
최근 연간 YoY
EPS 성장률
+21.8%
최근 연간 YoY
영업이익률
-159.9%
최근 연간
FCF 마진
-108.0%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| 매출 | $1.92B-39.9% | $3.20B-52.6% | $6.75B-64.2% | $18.88B |
| 매출총이익 | $1.05B-39.3% | $1.74B-15.8% | $2.06B-84.7% | $13.46B |
| 영업이익 | -$3.07B+22.1% | -$3.94B+6.9% | -$4.24B-145.0% | $9.42B |
| 순이익 | -$2.82B+20.8% | -$3.56B+24.5% | -$4.71B-156.4% | $8.36B |
| 희석 EPS | $-7.26+21.8% | $-9.28+24.7% | $-12.33-161.3% | $20.12 |
| EBITDA | -$2.54B+25.1% | -$3.39B+6.2% | -$3.62B-137.0% | $9.77B |
| 영업현금흐름 | -$1.87B+37.6% | -$3.00B+3.7% | -$3.12B-162.6% | $4.98B |
| 잉여현금흐름 | -$2.08B+48.8% | -$4.05B-6.0% | -$3.83B-183.5% | $4.58B |
| 총자산 | $12.34B-12.8% | $14.14B-23.2% | $18.43B-28.7% | $25.86B |
| 총부채 | $1.30B+74.7% | $747.00M-39.9% | $1.24B+3.6% | $1.20B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
MRNA 실적·배당 일정
매출 하단
$827.00M
EPS 하단
$-1.60
매출 상단
$943.80M
실적 발표일
2026-11-05
D-65
EPS 상단
$-0.80
매출 컨센서스
$876.64M
EPS 컨센서스
$-1.18
뉴스
MRNA 관련 최신 기사
규제·법률Moderna (MRNA) Soars 156% in August — Here’s What Propelled The Rally
Moderna Inc. (NASDAQ:MRNA) saw its share price soar by 156 percent in August—making it the highest-gaining stock for the month—driven primarily by the strong clinical trial results of its therapy candidate for melanoma, supported by a recent regulatory approval for its updated COVID-19 vaccines. It can be recalled that Moderna and Merck recently partnered for […]
Insider Monkey · Sep 1, 2026
제품·기술Stock Market Enjoys August Gains—Thanks to Unusual Winners
August was good to U.S. stock investors. All three major U.S. indexes finished the month in the green—something that hasn't happened since May. The tech-focused Nasdaq led the way, up 3.9% for the month.
The Wall Street Journal · Aug 31, 2026
일반There Was No Beating Moderna in August. These Are the Best and Worst S&P 500 Stocks for the Month.
Moderna stock surged 158% in August to lead the S&P 500, while Edison International plunged 27% to rank last in the index.
Barrons.com · Aug 31, 2026
일반8 Stocks Turn $100,000 Into $12.7 Million In 8 Months
August turned out to be a pretty good month for S&P 500 investors. And some stocks wound up having a great month.
Investor's Business Daily · Aug 31, 2026
일반Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results Encouraging
August has been a great month for the shares of Merck & Co., Inc. (NYSE:MRK) and Moderna Inc. (NASDAQ:MRNA), to say the least. The former’s stock closed 12.6% higher and the latter’s stock closed 176% higher on August 19th. The stocks surged after a major announcement from Moderna Inc. (NASDAQ:MRNA) shared the results from its […]
Insider Monkey · Aug 31, 2026
제품·기술Dolly Parton Life of Philanthropy May Have Kept Singer From Billionaire Status: ‘I Don’t Work for Money, Never Did’
Legendary singer and actress Dolly Parton passed away on Tuesday at the age of 80. While she was best known for her role in shaping global entertainment and, to many, as the “Queen of Country,” Parton leaves behind one of...
Benzinga · Aug 31, 2026
일반Is It Too Late to Buy Moderna Stock After Its 127% Surge?
Moderna could be on the verge of a breakthrough, but the biotech's MRNA cancer vaccine catalyst is overly priced in.
Motley Fool · Aug 30, 2026
일반Merck (MRK) Posts First Positive Phase 3 Result For Personalized mRNA Melanoma Therapy
Merck (NYSE:MRK) and Moderna report the first positive Phase 3 results for an individualized mRNA neoantigen cancer therapy in melanoma patients. The therapy was tested in combination with Merck's immunotherapy KEYTRUDA in a Phase 3 trial setting. This marks the first time an mRNA-based individualized neoantigen approach has shown clinically meaningful and statistically significant Phase 3 data in cancer. The result signals a potential new path for personalized cancer vaccines with...
Simply Wall St. · Aug 30, 2026
일반Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer Trial
The health-care sector was on track for its strongest week since June 26, with the Health Care index rising more than 4% in the five trading days leading up to August 21, compared to a 7.9% increase in late June. The spark was a single piece of clinical trial news: Moderna Inc. (NASDAQ:MRNA) and Merck […]
Insider Monkey · Aug 30, 2026
규제·법률What Do Moderna (MRNA) FDA Vaccine Approvals Mean For Its Respiratory Push?
Moderna (NasdaqGS:MRNA) received FDA approval for updated Spikevax and mNEXSPIKE COVID-19 vaccines tailored to the latest SARS-CoV-2 subvariant. The FDA also cleared mFlusiva, Moderna's first mRNA based influenza vaccine for adults aged 50 and over. These approvals expand Moderna's respiratory vaccine portfolio and mark the first FDA authorized mRNA flu shot for older adults. To see how other companies in this space are using similar technology, explore 39 healthcare AI...
Simply Wall St. · Aug 30, 2026
홀더
MRNA 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
80.5%
기관 보유 (유동주식)
86.8%
내부자 보유
7.3%
기관 수
1,091
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| FMR, LLC | 51.86M | $7.28B | 13.0% | 13.6% | Jun 30, 2026 |
| Blackrock Inc. | 30.60M | $4.29B | 7.7% | 3.3% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 23.21M | $3.26B | 5.8% | 1.5% | Jun 30, 2026 |
| Capital World Investors | 22.28M | $3.13B | 5.6% | 19.1% | Jun 30, 2026 |
| BAILLIE GIFFORD & CO | 18.21M | $2.56B | 4.6% | -8.9% | Jun 30, 2026 |
| State Street Corporation | 15.73M | $2.21B | 3.9% | 5.8% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 15.58M | $2.19B | 3.9% | -0.2% | Jun 30, 2026 |
| Geode Capital Management, LLC | 9.71M | $1.36B | 2.4% | 2.9% | Jun 30, 2026 |
| Morgan Stanley | 9.54M | $1.34B | 2.4% | 12.6% | Jun 30, 2026 |
| Theleme Partners LLP | 8.06M | $1.13B | 2.0% | 0.1% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.